Fire1 raises $120M for breakthrough heart failure management tech
January 7, 2025
Fire1 announced today that it completed a $120 million financing round to accelerate the advancement of its heart failure management system.
Fire1 announced today that it completed a $120 million financing round to accelerate the advancement of its heart failure management system.
Medtronic (NYSE: MDT)+
today announced CE mark approval for its Harmony transcatheter pulmonary valve (TPV) system
IceCure Medical (Nasdaq:ICCM) announced today that it received an intention to grant notice from the European Patent Office.
Age-related macular degeneration (AMD) is the leading cause of vision loss in individuals over 65, characterized by abnormal changes in the macular, resulting in reduced vision and distorted objects. Dry AMD accounts for 90% of all AMD cases, with relatively mild vision impairment; however, approximately 30% progress to the severe vision loss associated with wet AMD within 10 years.
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant.
MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.
MILPITAS, Calif., Dec. 5, 2024 /PRNewswire/ — LifeSignals, Inc. today announced that the UbiqVue 2A Multiparameter System has received EU MDR Certification, marking another significant milestone in deploying continuous wireless patient monitoring for population health management following FDA 510(k) Clearance last month.
GE HealthCare (Nasdaq:GEHC) today announced its new Pristina Via mammography system designed to enhance the screening experience.
Align Technology (Nasdaq:ALGN) announced today that it received CE mark for its Invisalign palatal expander system.
SAN FRANCISCO, Nov. 14, 2024 /PRNewswire/ — Eko Health, a pioneer in applying artificial intelligence for early detection of heart and lung diseases, today announced the issuance of a Category III Current Procedural Terminology (CPT) code by the American Medical Association (AMA) for its SENSORA™ platform. The newly issued Category III CPT code will be effective on July 1, 2025, and is the first step to coverage and reimbursement for SENSORA™, bringing advanced heart disease detection to clinicians across the U.S.